CompletedPhase 3NCT01868269
Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)
Studying Neuroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institut Curie
- Principal Investigator
- Gudrun Schleiermacher, MDInstitut Curie
- Intervention
- Dexamethasone acetate(drug)
- Enrollment
- 102 enrolled
- Eligibility
- 8 years · All sexes
- Timeline
- 2013 – 2025
Study locations (30)
- St. Anna Kinderkrebsforschung e.V. CHILDREN'S CANCER RESEARCH INSTITUTE, Vienna, Austria
- Chu de Bicetre, Le Kremlin-Bicêtre, LE Kremlin Bicetre, France
- Centre Oscar Lambret, Lille, Lille Cedex, France
- Centre Leon Berard, Lyon, LYON Cedex 08, France
- Hopita D'Enfants de La Timone, Marseille, Marseille Cedex 5, France
- Hopital Arnaud de Villeneuve, Montpellier, Montpellier Cedex 4, France
- Chr de Nantes, Nantes, Nantes Cedex01, France
- Chu de Nice Archet 2, Nice, NICE Cedex 03, France
- Ch Trousseau, Paris, Paris Cedex 12, France
- Chu Hopital Sud, Rennes, Rennes Cedex 02, France
- Chu de Rouen, Rouen, Rouen Cedex, France
- CHU DE STRASBOURG HOPITAL Hautepierre, Strasbourg, Strasbourg Cedex, France
- Chu Toulouse Hopital Des Enfants, Toulouse, Toulouse Cedex 9, France
- Chu Amiens, Amiens, France
- Chu Angers, Angers, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01868269 on ClinicalTrials.govOther trials for Neuroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07549321A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma PatientsRenaissance Pharma Ltd.
- RECRUITINGPHASE1, PHASE2NCT06625190Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsUniversity of Florida
- RECRUITINGPHASE1NCT07172958Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)Children's National Research Institute
- RECRUITINGPHASE2NCT07085338A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07399821An Imaging Study of Anti-GD2-800CW in Patients With NeuroblastomaPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE1NCT06995872Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory NeuroblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT06814496Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsUniversity of Arizona
- RECRUITINGPHASE1NCT07087002GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young AdultsStanford University